Vericel Corporation (NASDAQ:VCEL) Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. increased its stake in Vericel Corporation (NASDAQ:VCEL - Free Report) by 2.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 593,933 shares of the biotechnology company's stock after buying an additional 15,221 shares during the quarter. Victory Capital Management Inc. owned about 1.18% of Vericel worth $26,501,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the stock. Kornitzer Capital Management Inc. KS lifted its holdings in Vericel by 73.3% during the 1st quarter. Kornitzer Capital Management Inc. KS now owns 20,800 shares of the biotechnology company's stock worth $928,000 after buying an additional 8,800 shares during the last quarter. TimesSquare Capital Management LLC lifted its holdings in Vericel by 3.2% during the 1st quarter. TimesSquare Capital Management LLC now owns 652,465 shares of the biotechnology company's stock worth $29,113,000 after buying an additional 20,305 shares during the last quarter. New York State Common Retirement Fund lifted its holdings in Vericel by 0.9% during the 1st quarter. New York State Common Retirement Fund now owns 862,331 shares of the biotechnology company's stock worth $38,477,000 after buying an additional 7,429 shares during the last quarter. Mutual of America Capital Management LLC lifted its holdings in Vericel by 5.9% during the 1st quarter. Mutual of America Capital Management LLC now owns 158,930 shares of the biotechnology company's stock worth $7,091,000 after buying an additional 8,789 shares during the last quarter. Finally, Cerity Partners LLC lifted its holdings in Vericel by 10.1% during the 1st quarter. Cerity Partners LLC now owns 65,384 shares of the biotechnology company's stock worth $2,917,000 after buying an additional 5,988 shares during the last quarter.

Analyst Ratings Changes

Several brokerages have recently issued reports on VCEL. Truist Financial lowered their price target on Vericel from $61.00 to $51.00 and set a "buy" rating on the stock in a research report on Friday, April 11th. Wall Street Zen cut Vericel from a "hold" rating to a "sell" rating in a report on Monday, May 12th. Finally, Stephens restated an "overweight" rating and issued a $67.00 target price on shares of Vericel in a report on Monday, June 16th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $61.14.

Vericel Price Performance

Shares of NASDAQ VCEL opened at $35.46 on Tuesday. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of 1,182.39 and a beta of 1.32. The business has a 50-day moving average of $41.54 and a 200-day moving average of $46.79. Vericel Corporation has a fifty-two week low of $34.87 and a fifty-two week high of $63.00.

Vericel (NASDAQ:VCEL - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.14). The business had revenue of $52.60 million during the quarter, compared to analyst estimates of $53.86 million. Vericel had a net margin of 1.25% and a return on equity of 1.09%. The firm's quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.08) earnings per share. On average, sell-side analysts expect that Vericel Corporation will post 0.14 EPS for the current year.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Corporation (NASDAQ:VCEL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.